A novel vaccine delivery system: Biodegradable nanoparticles in thermosensitive hydrogel

Growth Factors

Volumn 29, Issue 6, 2011, Pages 290-297

  Wu, Qin Jie ^a   Zhu, Xue Chen ^a   Xiao, Xiong ^a   Wang, Pan ^a   Xiong, Da Ke ^a   Gong, Chang Yang ^a   Wang, Yong Sheng ^a   Yang, Li ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

BFGF; Biodegradable; Hydrogel; Nanoparticles; Thermosensitive; Vaccine

Indexed keywords

ANTIGEN; FIBROBLAST GROWTH FACTOR; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CANCER IMMUNIZATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; EMULSION; ENVIRONMENTAL TEMPERATURE; FEMALE; HEAT SENSITIVITY; HUMORAL IMMUNITY; HYDROGEL; IMMUNE RESPONSE; IMMUNOGENICITY; LUNG CARCINOMA; METASTASIS; MOUSE; NONHUMAN; PHASE TRANSITION; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; CANCER VACCINES; CARCINOMA, LEWIS LUNG; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; HYDROGELS; MICE; MICE, INBRED C57BL; NANOCAPSULES; VACCINATION;

EID: 80155192341     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2011.624517     Document Type: Article

References (27)

1. Chong CSW, Cao M, Wong WW, Fischer KP, Addison WR, Kwon GS, Tyrrell DL, Samuel J. 2005. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J Control Release 102: 85-99 (Pubitemid 40093778)
2. Coeshott CM, Smithson SL, Verderber E, Samaniego A, Blonder JM, Rosenthal GJ,Westerink MAJ. 2004. Pluronicw F127-based systemic vaccine delivery systems. Vaccine 22:2396-2405 (Pubitemid 38757336)
3. Gander B. 2005. Trends in particulate antigen and DNA delivery systems for vaccines. Adv Drug Deliv Rev 57:321-323 (Pubitemid 39550964)
4. Gong C-Y, Shi S, Peng X-Y, Kan B, Yang L, Huang M-J, Luo F, Zhao X, Wei Y-Q, Qian Z-Y. 2009a. Biodegradable thermosensitive injectable PEG-PCL-PEG hydrogel for bFGF antigen delivery to improve humoral immunity. Growth Factors 27: 377-383
5. Gong CY, Dong PW, Shi S, Fu SZ, Yang JL, Guo G, Zhao X, Wei YQ, Qian ZY. 2009b. Thermosensitive PEG-PCL-PEG hydrogel controlled drug delivery system: Sol-gel-sol transition and in vitro drug release study. J Pharm Sci 98:3707-3717
6. Gong CY, Shi S, DongPW, Kan B, Gou ML,Wang XH, Li XY, Luo F, Zhao X,Wei Y, Qian Z. 2009c. Synthesis and characterization of PEG-PCL-PEG thermosensitive hydrogel. Int J Pharm 365: 89-99
7. GongCY, Shi S,Wu L,GouML,YinQQ,GuoQF, DongPW, Zhang F, Luo F, Zhao X, Wei Y, Qian Z. 2009d. Biodegradable in situ gel-forming controlled drug delivery system based on thermosensitive PCL-PEG-PCL hydrogel. Part 2: Sol-gel-sol transition and drug delivery behavior. Acta Biomater 5:3358-3370
8. Gou M, Dai M, Gu Y, Li X,Wen Y, Yang L,Wang K,Wei Y, Qian Z. 2008. BFGF loaded biodegradable PCL-PEG-PCL copolymeric nanoparticles: Preparation, in vitro release and immunogenicity study. J Nanosci Nanotechnol 8:1-5
9. Gupta RK. 1998. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 32:155-172 (Pubitemid 28267407)
10. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK. 1993. Adjuvants-a balance between toxicity and adjuvanticity. Vaccine 11:293-306
11. Huang Y-Y, Wang C-H. 2006. Pulmonary delivery of insulin by liposomal carriers. J Control Release 113:9-14 (Pubitemid 43818162)
12. Jilek S, Merkle HP, Walter E. 2005. DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv Drug Deliv Rev 57:377-390 (Pubitemid 39550966)
13. Julie Westerink MA, Louise Smithson S, Srivastava N, Blonder J, Coeshott C, Rosenthal GJ. 2002. ProJuvantTM (Pluronicw F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid. Vaccine 20:711-723 (Pubitemid 34015810)
14. Kang ML, Jiang H-L, Kang SG, Guo DD, Lee DY, Cho C-S, Yoo HS. 2007. Pluronicw F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin. Vaccine 25:4602-4610 (Pubitemid 46734533)
15. Liu MA. 1999. Topic in review: Vaccines in the 21st century.West J Med 171:319-322
16. Man S, Tabi Z. 2006. Human cancer vaccines. Adv Drug Deliv Rev 58:899-901 (Pubitemid 44709260)
17. Moll H. 2004. Antigen delivery by dendritic cells. Int J Med Microbiol 294:337-344 (Pubitemid 39381970)
18. OHagan DT, Rappuoli R. 2004a. Novel approaches to vaccine delivery. Pharm Res 21:1519-1530 (Pubitemid 41184379)
19. OHagan DT, Rappuoli R. 2004b. The safety of vaccines. Drug Discov Today 9:846-854 (Pubitemid 39286098)
20. OHagan DT, Rappuoli R. 2006. Novel approaches to pediatric vaccine delivery. Adv Drug Deliv Rev 58:29-51
21. OHagan DT, Valiante NM. 2003. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2: 727-735 (Pubitemid 37361788)
22. OHagan DT, MacKichan ML, Singh M. 2001. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 18:69-85 (Pubitemid 32889607)
23. Peek LJ, Middaugh CR, Berkland C. 2008. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev 60:915-928
24. Poland GA, Murray D, Bonilla-Guerrero R. 2002. Science, medicine, and the future: New vaccine development. Br Med J 324:1315-1319 (Pubitemid 34606776)
25. Singh M, OHagan D. 1999. Advances in vaccine adjuvants. Nat Biotech 17:1075-1081 (Pubitemid 29533545)
26. Singh M, OHagan DT. 2002. Recent advances in vaccine adjuvants. Pharm Res 19:715-728 (Pubitemid 34686729)
27. Singh M, Li XM, Wang H, McGee JP, Zamb T, Koff W, Wang CY, OHagan DT. 1998. Controlled release microparticles as a single dose diphtheria toxoid vaccine: Immunogenicity in small animal models. Vaccine 16:346-352 (Pubitemid 28010769)